I'm looking for

Industry Supported Symposia

Industry Supported Symposia (ISS) are unique forums for presenting educational information to Society of Gynecologic Oncology (SGO) Allied Health Professionals Meeting attendees, free of charge. Please view a listing of the ISS sessions below and note that registration is not required. For each session, meals will be provided by the supporting companies.

SGO does not provide CE credit or endorse the content, products, or services presented in ISS sessions, and will not share any ISS recordings or materials.

 

ISS I: Appropriate Patients with Certain Types of Advanced Gynecologic Cancers (Endometrial and Cervical)

Friday, October 10, 11:00 a.m. – 12:30 p.m. MT

Supporting Company: Merck

Speakers: TBD

Location: Colorado Ballroom E-F     

Description: Education of the AH audience on the history and evolution of biomarkers in ovarian and endometrial cancers. 

Learning objectives:

  1. Review up-to-date advances in biomarker-driven management of patients with ovarian or endometrial cancer and implications for outcomes.
  2. Discuss how currently actionable biomarkers impact treatment selection for these diseases.
  3. Consider the future evolution in biomarkers and management of patients with gynecological malignancies

 

ISS II: Supporting Appropriate Patients through the JEMPERLI (dostarlimab-gxly) Treatment Experience: Considerations for Nurses

Saturday, October 11, 7:00 – 8:30 a.m. MT

Supporting Company: GSK

Speaker: Kimberly Halla, MSN, FNP-C

Location: Colorado Ballroom E-F   

Description: Endometrial Cancer Background: Review the incidence of endometrial cancer and the importance of MMR/MSI biomarker testing • RUBY Part 1 Trial Results: Become familiar with the efficacy and safety data • Dosage & Administration: Learn about the recommended dosage and proper administration • Monitoring Adverse Reactions: Understand the potential adverse reactions and learn how to help monitor them • Important Safety Information • Summary  

Learning objectives:

  1. Review the incidence of endometrial cancer and the importance of MMR/MSI biomarker testing
  2. Discuss the RUBY Part 1 Trial Results including:
    • Review efficacy and safety data and dosage and administration
    • Monitor adverse reactions
    • Identify important safety information

 

ISS III: Understanding Tivdak

Saturday, October 11, 11:00 a.m. – 12:30 p.m. MT

Supporting Company: Pfizer

Speaker: Kimberly Halla, MSN, FNP-C

Location: Colorado Ballroom E-F   

Description: Learn about NEW updates for Tivdak – a novel therapy for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. While Tivdak was the first antibody drug conjugate (ADC) approved for use in gynecologic malignancies in 2021, it received its full FDA approval in 2024 including key updates to overall survival data, safety information and eye care regimen. There are now multiple medications in gynecologic oncology requiring eye care mitigation plans. The audience will learn how to specifically manage the eye care regimen for Tivdak from our expert APP faculty. This interactive session will engage audience members in a discussion about Tivdak’s proposed mechanism of action and clinical trial outcomes. Our faculty will explore the role of Tissue Factor in solid tumors and its role in Tivdak’s unique cell-killing effect. Additionally, they will review the innovaTV 301 trial design and study outcomes, including Tivdak’s unprecedented overall survival data. Faculty will provide a critical perspective on Tivdak’s safety profile and patient management, including a review and discussion of ocular adverse reactions experienced by patients on trial and Tivdak’s associated eye care requirements. Lastly, the session will close with an interactive Q&A session in which audience members questions will be addressed based on their first-hand clinical experience treating cervical cancer patients with Tivdak. 

Learning objectives:

  1. Review Tivdak’s updated FDA approval, overall survival data, and safety profile
  2. Understand Tivdak’s mechanism of action and the role of Tissue Factor in solid tumors
  3. Interpret results from the innovaTV 301 trial
  4. Learn best practices for managing Tivdak’s eye care regimen and mitigating ocular side effects
  5. Apply expert insights to patient management in recurrent or metastatic cervical cancer